Acurx Pharmaceuticals LLC Cash Flow Conversion Efficiency
Acurx Pharmaceuticals LLC cash flow conversion efficiency. Based on the latest financial reports, Acurx Pharmaceuticals LLC (ACXP) has a cash flow conversion efficiency ratio of -0.210x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.71 Million) by net assets ($8.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Acurx Pharmaceuticals LLC (2019–2025)
Cash flow conversion efficiency of Acurx Pharmaceuticals LLC from 2019 to 2025. This chart illustrates how Acurx Pharmaceuticals LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ACXP live share price for real-time trading data and today's change.
Acurx Pharmaceuticals LLC Cash Flow Conversion Ratio Explained
Acurx Pharmaceuticals LLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Acurx Pharmaceuticals LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acurx Pharmaceuticals LLC ranked by their cash flow conversion efficiency. Also see Acurx Pharmaceuticals LLC (ACXP) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Newton Golf Company
NASDAQ:NWTG
|
0.492x |
|
Horus AG
STU:HRU
|
N/A |
|
Zonte Metals Inc
V:ZON
|
0.000x |
|
Erika Carmel-Tech Ltd
TA:ERKA
|
-0.383x |
|
Sawang Export Public Company Limited
BK:SAWANG
|
0.001x |
|
Innity Corporation Bhd
KLSE:0147
|
-0.154x |
|
NanoVibronix Inc
NASDAQ:NAOV
|
-0.046x |
|
Pure Biologics Spólka Akcyjna
WAR:PUR
|
0.011x |
Annual Cash Flow Conversion Efficiency for Acurx Pharmaceuticals LLC (2019–2025)
The table below shows the annual cash flow conversion efficiency of Acurx Pharmaceuticals LLC from 2019 to 2025. Review financial flexibility index of Acurx Pharmaceuticals LLC to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.27 Million | $-6.79 Million | -1.288x | +92.37% |
| 2024-12-31 | $615.12K | $-10.38 Million | -16.880x | -703.75% |
| 2023-12-31 | $4.67 Million | $-9.80 Million | -2.100x | -103.69% |
| 2022-12-31 | $7.32 Million | $-7.54 Million | -1.031x | -155.22% |
| 2021-12-31 | $12.41 Million | $-5.01 Million | -0.404x | +67.44% |
| 2020-12-31 | $2.70 Million | $-3.35 Million | -1.241x | +74.48% |
| 2019-12-31 | $819.85K | $-3.99 Million | -4.861x | -- |
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more